Case Study: Leading Global Pharmaceutical Company achieves faster enrollment — 700 patients randomized ahead of schedule with IQVIA Biotech

Enrollment of 700 Patients Completed Ahead of Schedule

Leading Global Pharmaceutical Company selected IQVIA to recruit patients for two Phase II psoriasis studies—300 scalp/body and 400 body‑only patients—across 33–40 sites. The challenge was to randomize 700 patients within an 18‑week window from early May to the end of August, a seasonally difficult period for psoriasis enrollment that risked delaying the development program.

IQVIA implemented its patient recruitment service—combining an “overlap” site strategy, predictive enrollment analytics, and a heavily front‑loaded advertising campaign with daily monitoring and site‑level adjustments. The result: full randomization in 16.5 weeks (scalp/body) and 15.5 weeks (body‑only), saving 1.5 and 2.5 weeks respectively, meeting targets ahead of schedule while spending just over 50% of the planned advertising budget.